Hepatic impairment No dose adjustment is needed in patients with moderate or reasonable (Youngster-Pugh A or B) hepatic impairment (see section five.2). Publicity to midostaurin and its active metabolite CGP62221 is significantly lessen in clients with significant hepatic impairment than that in patients with usual hepatic operate (see section 5. https://jamese196vaf9.blogdosaga.com/profile